Q) What is TELMIDUCE H 40MG TABLET used for? A) TELMIDUCE H 40MG TABLET belongs to antihypertensives which are used to lower blood pressure in hypertensive patients. Hypertension, also known as high blood pressure, is a condition in which the heart pumps blood with more force than usual and the pressure exerted by the blood on blood vessels increases. This results in more pressure on the heart. If hypertension is untreated, it can result to heart attack and other heart related problems. It can be difficult to self-diagnose hypertension because in most cases, it doesnt show any symptoms, until the condition becomes severe. Get your blood pressure checked regularly by the doctor.
Q) Can I take TELMIDUCE H 40MG TABLET with calcium supplements? A) No, it is advised not to take TELMIDUCE H 40MG TABLET with calcium supplements. TELMIDUCE H 40MG TABLET may result in increasing levels of calcium in the body. If you take calcium supplements with TELMIDUCE H 40MG TABLET, it may lead to hypercalcemia and result in adverse effects. If you are taking calcium supplements, please inform your doctor. He/she may suggest an alternate therapy.
Q) What if I take more than the prescribed dose? A) If you take more than the prescribed dose by accident, immediately inform your family members or friends and call your doctor or go to the nearest hospital. Do not panic if you experience dizziness, vomiting, slow heartbeat, low blood pressure, irregular heartbeat, sleepiness or muscle cramps. Inform your doctor if you experience any additional symptoms.
Q) Can I take TELMIDUCE H 40MG TABLET if I have liver damage? A) Yes, you can take TELMIDUCE H 40MG TABLET even if you have liver damage. However, your doctor will prescribe you lower dose of the medicine. This is to prevent the burden on liver and to prevent further damage of the liver.
Q) How do I store TELMIDUCE H 40MG TABLET? A) Keep TELMIDUCE H 40MG TABLET away from children. Store it at room temperature. Avoid keeping TELMIDUCE H 40MG TABLET in freezing conditions or in direct sunlight.
